David Barton
Concepts (335)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA, Viral | 41 | 2025 | 656 | 6.910 |
Why?
| | Poliovirus | 31 | 2025 | 85 | 5.790 |
Why?
| | Brain Injuries, Traumatic | 9 | 2025 | 360 | 3.200 |
Why?
| | Virus Replication | 19 | 2025 | 483 | 3.050 |
Why?
| | Viral Proteins | 12 | 2025 | 342 | 2.680 |
Why?
| | Endoribonucleases | 9 | 2014 | 81 | 2.250 |
Why?
| | Recombination, Genetic | 4 | 2025 | 204 | 1.940 |
Why?
| | HeLa Cells | 28 | 2020 | 636 | 1.480 |
Why?
| | Picornaviridae | 3 | 2020 | 18 | 1.430 |
Why?
| | Enterovirus C, Human | 2 | 2025 | 3 | 1.250 |
Why?
| | Ribavirin | 3 | 2020 | 91 | 1.240 |
Why?
| | Snake Bites | 2 | 2019 | 29 | 1.190 |
Why?
| | Blepharoptosis | 1 | 2025 | 11 | 0.930 |
Why?
| | Blood-Brain Barrier | 2 | 2024 | 138 | 0.930 |
Why?
| | Multiple Organ Failure | 1 | 2025 | 128 | 0.900 |
Why?
| | Viral Nonstructural Proteins | 3 | 2020 | 65 | 0.870 |
Why?
| | Hepacivirus | 6 | 2014 | 261 | 0.850 |
Why?
| | Polyadenylation | 2 | 2015 | 42 | 0.830 |
Why?
| | Emergency Medical Services | 2 | 2023 | 552 | 0.830 |
Why?
| | Agkistrodon | 2 | 2023 | 5 | 0.810 |
Why?
| | Air Ambulances | 1 | 2023 | 32 | 0.790 |
Why?
| | Nucleic Acid Conformation | 11 | 2010 | 728 | 0.790 |
Why?
| | Sinusitis | 1 | 2025 | 221 | 0.760 |
Why?
| | RNA | 5 | 2020 | 921 | 0.710 |
Why?
| | Drug Resistance, Viral | 3 | 2020 | 116 | 0.700 |
Why?
| | Murine hepatitis virus | 1 | 2020 | 16 | 0.690 |
Why?
| | Protein Biosynthesis | 12 | 2008 | 433 | 0.670 |
Why?
| | Heart Arrest | 1 | 2024 | 339 | 0.660 |
Why?
| | Antiviral Agents | 5 | 2020 | 744 | 0.650 |
Why?
| | Hypogonadism | 2 | 2020 | 92 | 0.640 |
Why?
| | Hydrocortisone | 1 | 2021 | 322 | 0.620 |
Why?
| | Coral Snakes | 1 | 2019 | 3 | 0.620 |
Why?
| | RNA, Messenger | 7 | 2008 | 2833 | 0.610 |
Why?
| | Bupivacaine | 1 | 2018 | 32 | 0.590 |
Why?
| | Polyribosomes | 2 | 2008 | 24 | 0.580 |
Why?
| | Nerve Block | 1 | 2018 | 73 | 0.550 |
Why?
| | Tomography, X-Ray Computed | 2 | 2025 | 2691 | 0.550 |
Why?
| | Amino Acid Substitution | 5 | 2020 | 307 | 0.530 |
Why?
| | RNA Stability | 4 | 2014 | 117 | 0.510 |
Why?
| | Viral Core Proteins | 3 | 2003 | 18 | 0.510 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1587 | 0.510 |
Why?
| | Cognitive Dysfunction | 1 | 2021 | 383 | 0.510 |
Why?
| | Base Sequence | 14 | 2012 | 2181 | 0.500 |
Why?
| | Leucine | 1 | 2016 | 111 | 0.500 |
Why?
| | Humans | 56 | 2025 | 137585 | 0.450 |
Why?
| | Wounds and Injuries | 3 | 2025 | 758 | 0.450 |
Why?
| | Ribonuclease, Pancreatic | 1 | 2014 | 12 | 0.430 |
Why?
| | RNA Cleavage | 1 | 2014 | 10 | 0.430 |
Why?
| | Templates, Genetic | 3 | 2010 | 63 | 0.430 |
Why?
| | Neurofilament Proteins | 2 | 2024 | 52 | 0.430 |
Why?
| | Influenza A virus | 1 | 2014 | 107 | 0.430 |
Why?
| | DNA-Directed RNA Polymerases | 3 | 2020 | 57 | 0.410 |
Why?
| | Transcription, Genetic | 7 | 2015 | 1457 | 0.400 |
Why?
| | Pain | 1 | 2018 | 756 | 0.400 |
Why?
| | Molecular Sequence Data | 11 | 2012 | 2900 | 0.400 |
Why?
| | Uridine | 2 | 2009 | 30 | 0.390 |
Why?
| | Biomarkers | 4 | 2025 | 4149 | 0.390 |
Why?
| | Genome, Viral | 5 | 2025 | 144 | 0.390 |
Why?
| | Poly U | 2 | 2010 | 4 | 0.380 |
Why?
| | Poly A | 2 | 2010 | 51 | 0.370 |
Why?
| | Host-Pathogen Interactions | 1 | 2014 | 364 | 0.360 |
Why?
| | Conserved Sequence | 2 | 2008 | 239 | 0.350 |
Why?
| | Young Adult | 9 | 2025 | 13209 | 0.350 |
Why?
| | Cysteine Endopeptidases | 2 | 2008 | 73 | 0.340 |
Why?
| | Ribosomes | 2 | 2004 | 186 | 0.340 |
Why?
| | Poly C | 2 | 2008 | 4 | 0.340 |
Why?
| | Open Reading Frames | 2 | 2008 | 123 | 0.330 |
Why?
| | Deoxycytosine Nucleotides | 1 | 2009 | 11 | 0.320 |
Why?
| | Mutation | 9 | 2020 | 3958 | 0.310 |
Why?
| | Male | 19 | 2025 | 67762 | 0.300 |
Why?
| | Enterovirus | 2 | 2012 | 86 | 0.300 |
Why?
| | Alcohol Drinking | 1 | 2016 | 828 | 0.300 |
Why?
| | Glasgow Outcome Scale | 2 | 2025 | 10 | 0.300 |
Why?
| | Pain Management | 2 | 2025 | 352 | 0.300 |
Why?
| | Adult | 14 | 2025 | 37929 | 0.300 |
Why?
| | Eukaryotic Initiation Factor-4G | 1 | 2008 | 5 | 0.290 |
Why?
| | Uridine Monophosphate | 2 | 2008 | 15 | 0.280 |
Why?
| | Base Composition | 1 | 2007 | 78 | 0.270 |
Why?
| | Dinucleoside Phosphates | 1 | 2007 | 27 | 0.270 |
Why?
| | Glasgow Coma Scale | 2 | 2024 | 186 | 0.260 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1000 | 0.260 |
Why?
| | Middle Aged | 11 | 2025 | 33479 | 0.250 |
Why?
| | Sufentanil | 1 | 2025 | 2 | 0.240 |
Why?
| | Mutagenesis, Site-Directed | 3 | 2016 | 375 | 0.230 |
Why?
| | Ribonucleases | 1 | 2004 | 55 | 0.230 |
Why?
| | Intracranial Hemorrhage, Traumatic | 1 | 2024 | 10 | 0.230 |
Why?
| | Aged | 9 | 2025 | 23961 | 0.220 |
Why?
| | Dendritic Spines | 2 | 2016 | 65 | 0.220 |
Why?
| | Kinetics | 5 | 2008 | 1670 | 0.220 |
Why?
| | RNA, Ribosomal | 3 | 2014 | 168 | 0.210 |
Why?
| | Protein Binding | 5 | 2020 | 2224 | 0.210 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 399 | 0.210 |
Why?
| | Narcotic Antagonists | 1 | 2025 | 181 | 0.210 |
Why?
| | Opiate Substitution Treatment | 1 | 2025 | 155 | 0.210 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2025 | 179 | 0.200 |
Why?
| | Prospective Studies | 5 | 2025 | 7604 | 0.200 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2023 | 48 | 0.200 |
Why?
| | 5' Untranslated Regions | 4 | 2012 | 58 | 0.190 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 117 | 0.190 |
Why?
| | Uridine Triphosphate | 1 | 2001 | 10 | 0.190 |
Why?
| | Anaphylaxis | 1 | 2023 | 105 | 0.190 |
Why?
| | Trauma Centers | 1 | 2024 | 421 | 0.190 |
Why?
| | Cell-Free System | 5 | 2008 | 53 | 0.190 |
Why?
| | Buprenorphine | 1 | 2025 | 173 | 0.180 |
Why?
| | Hepatitis C | 1 | 2004 | 271 | 0.180 |
Why?
| | Protein Conformation | 3 | 2015 | 934 | 0.180 |
Why?
| | Patient Acuity | 1 | 2021 | 47 | 0.180 |
Why?
| | Animals | 12 | 2023 | 36940 | 0.180 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2024 | 249 | 0.180 |
Why?
| | Female | 10 | 2025 | 73304 | 0.170 |
Why?
| | Plasmids | 4 | 2008 | 363 | 0.170 |
Why?
| | Models, Molecular | 4 | 2015 | 1570 | 0.170 |
Why?
| | Nucleotide Motifs | 1 | 2020 | 35 | 0.170 |
Why?
| | Computational Biology | 1 | 2025 | 644 | 0.170 |
Why?
| | Enterovirus B, Human | 1 | 2020 | 26 | 0.170 |
Why?
| | Sindbis Virus | 2 | 1991 | 10 | 0.160 |
Why?
| | Picornaviridae Infections | 1 | 2020 | 47 | 0.160 |
Why?
| | Carrier Proteins | 2 | 2009 | 771 | 0.160 |
Why?
| | Pituitary Gland | 1 | 2020 | 148 | 0.160 |
Why?
| | Brain Injuries | 2 | 2016 | 494 | 0.160 |
Why?
| | Injury Severity Score | 3 | 2024 | 522 | 0.160 |
Why?
| | Hypothalamus | 1 | 2020 | 153 | 0.160 |
Why?
| | Ribonuclease T1 | 2 | 2009 | 5 | 0.160 |
Why?
| | Mutation, Missense | 2 | 2019 | 341 | 0.150 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2009 | 91 | 0.150 |
Why?
| | Fascia | 1 | 2018 | 17 | 0.150 |
Why?
| | Femoral Nerve | 1 | 2018 | 18 | 0.150 |
Why?
| | Guanidine | 3 | 2009 | 21 | 0.150 |
Why?
| | Anesthetics, Local | 1 | 2018 | 80 | 0.140 |
Why?
| | Cohort Studies | 3 | 2024 | 5742 | 0.140 |
Why?
| | Apolipoprotein E4 | 1 | 2018 | 37 | 0.140 |
Why?
| | Injections | 1 | 2018 | 183 | 0.140 |
Why?
| | Opioid-Related Disorders | 1 | 2025 | 515 | 0.140 |
Why?
| | Mice | 7 | 2020 | 17787 | 0.140 |
Why?
| | Amino Acid Sequence | 4 | 2008 | 2139 | 0.140 |
Why?
| | Mice, Inbred C57BL | 5 | 2020 | 5757 | 0.130 |
Why?
| | Inflammation Mediators | 1 | 2020 | 513 | 0.130 |
Why?
| | Models, Genetic | 3 | 2008 | 600 | 0.130 |
Why?
| | Neuropsychological Tests | 2 | 2024 | 1023 | 0.130 |
Why?
| | Retrospective Studies | 6 | 2025 | 15657 | 0.130 |
Why?
| | Registries | 1 | 2024 | 2035 | 0.130 |
Why?
| | Peptide Initiation Factors | 1 | 1996 | 16 | 0.120 |
Why?
| | Alcohols | 1 | 2016 | 27 | 0.120 |
Why?
| | Nucleotides | 2 | 2008 | 125 | 0.120 |
Why?
| | Administration, Sublingual | 2 | 2025 | 12 | 0.120 |
Why?
| | Cell Line | 4 | 2014 | 2847 | 0.120 |
Why?
| | Microbial Sensitivity Tests | 1 | 2016 | 361 | 0.120 |
Why?
| | Time Factors | 5 | 2025 | 6828 | 0.120 |
Why?
| | Binding, Competitive | 2 | 2008 | 202 | 0.120 |
Why?
| | Risk Assessment | 1 | 2024 | 3457 | 0.110 |
Why?
| | DNA, Complementary | 2 | 2008 | 272 | 0.110 |
Why?
| | Cross-Sectional Studies | 2 | 2016 | 5472 | 0.110 |
Why?
| | Hydrolysis | 1 | 2014 | 177 | 0.110 |
Why?
| | Anti-Bacterial Agents | 1 | 2025 | 1809 | 0.110 |
Why?
| | RNA Precursors | 1 | 1995 | 154 | 0.110 |
Why?
| | RNA, Small Nuclear | 1 | 2014 | 37 | 0.110 |
Why?
| | White Matter | 1 | 2016 | 145 | 0.110 |
Why?
| | Gene Knockdown Techniques | 1 | 2014 | 327 | 0.110 |
Why?
| | Genetic Complementation Test | 3 | 2004 | 67 | 0.110 |
Why?
| | Sulfur Radioisotopes | 2 | 2008 | 15 | 0.100 |
Why?
| | RNA, Double-Stranded | 2 | 2004 | 57 | 0.100 |
Why?
| | Binding Sites | 2 | 2008 | 1303 | 0.100 |
Why?
| | Cells, Cultured | 1 | 2020 | 4193 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 1 | 2025 | 3566 | 0.100 |
Why?
| | Macrophages | 1 | 2020 | 1547 | 0.100 |
Why?
| | Protein Structure, Tertiary | 3 | 2012 | 861 | 0.100 |
Why?
| | Testosterone | 1 | 2016 | 409 | 0.100 |
Why?
| | Follow-Up Studies | 1 | 2021 | 5131 | 0.090 |
Why?
| | Autoantibodies | 1 | 2020 | 1496 | 0.090 |
Why?
| | Emergency Medical Technicians | 1 | 2012 | 36 | 0.090 |
Why?
| | Patient Care Management | 1 | 2012 | 57 | 0.090 |
Why?
| | Argonaute Proteins | 1 | 2012 | 27 | 0.090 |
Why?
| | Adolescent | 5 | 2021 | 21513 | 0.090 |
Why?
| | West Nile virus | 1 | 2012 | 43 | 0.090 |
Why?
| | Immune Evasion | 1 | 2012 | 58 | 0.090 |
Why?
| | West Nile Fever | 1 | 2012 | 54 | 0.090 |
Why?
| | Semliki forest virus | 1 | 1991 | 2 | 0.090 |
Why?
| | Genes, Viral | 1 | 1991 | 88 | 0.090 |
Why?
| | Alphavirus | 1 | 1991 | 21 | 0.090 |
Why?
| | Interferon Type I | 1 | 2012 | 140 | 0.090 |
Why?
| | Amyloid beta-Peptides | 1 | 2013 | 220 | 0.090 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2014 | 539 | 0.090 |
Why?
| | Physical Examination | 1 | 2012 | 241 | 0.090 |
Why?
| | Temperature | 3 | 2004 | 679 | 0.080 |
Why?
| | RNA, Untranslated | 1 | 2012 | 124 | 0.080 |
Why?
| | Logistic Models | 1 | 2016 | 2074 | 0.080 |
Why?
| | Cerebral Cortex | 1 | 2013 | 433 | 0.080 |
Why?
| | DNA Primers | 2 | 2004 | 515 | 0.080 |
Why?
| | Codon | 2 | 2007 | 89 | 0.080 |
Why?
| | Exoribonucleases | 1 | 2010 | 49 | 0.080 |
Why?
| | Mutagenesis | 2 | 2008 | 179 | 0.080 |
Why?
| | Uracil | 1 | 2008 | 31 | 0.070 |
Why?
| | Genes, Dominant | 1 | 2008 | 96 | 0.070 |
Why?
| | Base Pairing | 1 | 2008 | 64 | 0.070 |
Why?
| | Cytosine | 1 | 2008 | 49 | 0.070 |
Why?
| | Adenine Nucleotides | 1 | 2008 | 23 | 0.070 |
Why?
| | Epithelial Cells | 1 | 2014 | 1096 | 0.070 |
Why?
| | Cognition | 1 | 2016 | 1153 | 0.070 |
Why?
| | Oligoribonucleotides | 1 | 2008 | 52 | 0.070 |
Why?
| | Puromycin | 2 | 1999 | 10 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2004 | 2057 | 0.070 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 145 | 0.070 |
Why?
| | Prognosis | 1 | 2016 | 4030 | 0.070 |
Why?
| | Protein Processing, Post-Translational | 2 | 2008 | 465 | 0.070 |
Why?
| | RNA Caps | 2 | 2012 | 35 | 0.070 |
Why?
| | Depression | 1 | 2016 | 1397 | 0.070 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2008 | 177 | 0.060 |
Why?
| | Transdermal Patch | 1 | 2025 | 15 | 0.060 |
Why?
| | Administration, Cutaneous | 1 | 2025 | 129 | 0.060 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2005 | 95 | 0.060 |
Why?
| | MicroRNAs | 1 | 2012 | 692 | 0.060 |
Why?
| | Selection, Genetic | 1 | 2007 | 273 | 0.060 |
Why?
| | Sequence Deletion | 2 | 2004 | 183 | 0.060 |
Why?
| | Diffuse Axonal Injury | 1 | 2024 | 8 | 0.060 |
Why?
| | Phylogeny | 1 | 2008 | 904 | 0.060 |
Why?
| | Electronic Health Records | 1 | 2012 | 1069 | 0.060 |
Why?
| | Quality of Life | 1 | 2016 | 2892 | 0.050 |
Why?
| | Cytoplasm | 1 | 2004 | 274 | 0.050 |
Why?
| | Antivenins | 1 | 2023 | 36 | 0.050 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2023 | 59 | 0.050 |
Why?
| | Horses | 1 | 2023 | 111 | 0.050 |
Why?
| | Pain Measurement | 1 | 2025 | 521 | 0.050 |
Why?
| | Patients | 1 | 2023 | 175 | 0.050 |
Why?
| | Capsid | 1 | 2002 | 93 | 0.050 |
Why?
| | Poly G | 1 | 2001 | 2 | 0.050 |
Why?
| | Craniocerebral Trauma | 2 | 2016 | 170 | 0.050 |
Why?
| | Precipitin Tests | 1 | 2001 | 100 | 0.050 |
Why?
| | Risk Factors | 1 | 2016 | 10388 | 0.040 |
Why?
| | Medical Audit | 2 | 1991 | 78 | 0.040 |
Why?
| | Models, Biological | 1 | 2008 | 1783 | 0.040 |
Why?
| | Interferons | 1 | 2002 | 202 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2002 | 810 | 0.040 |
Why?
| | Anisomycin | 1 | 1999 | 2 | 0.040 |
Why?
| | Ricin | 1 | 1999 | 8 | 0.040 |
Why?
| | Recovery of Function | 1 | 2024 | 653 | 0.040 |
Why?
| | Cycloheximide | 1 | 1999 | 55 | 0.040 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 1999 | 18 | 0.040 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1999 | 47 | 0.040 |
Why?
| | Diphtheria Toxin | 1 | 1999 | 66 | 0.040 |
Why?
| | Phosphorylation | 1 | 2024 | 1759 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2001 | 396 | 0.040 |
Why?
| | Protein Domains | 1 | 2020 | 289 | 0.040 |
Why?
| | Apolipoprotein E3 | 1 | 2018 | 2 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2002 | 493 | 0.040 |
Why?
| | Capillary Permeability | 1 | 2018 | 145 | 0.030 |
Why?
| | Inflammation | 2 | 2020 | 2837 | 0.030 |
Why?
| | Unconsciousness | 1 | 2016 | 19 | 0.030 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1996 | 26 | 0.030 |
Why?
| | Fluoresceins | 1 | 2016 | 47 | 0.030 |
Why?
| | Chromatography, Affinity | 1 | 1996 | 88 | 0.030 |
Why?
| | Subcellular Fractions | 1 | 1996 | 82 | 0.030 |
Why?
| | Maze Learning | 1 | 2016 | 103 | 0.030 |
Why?
| | Indicators and Reagents | 1 | 1996 | 106 | 0.030 |
Why?
| | Cytidine Triphosphate | 1 | 1995 | 16 | 0.030 |
Why?
| | Guanidines | 1 | 1995 | 39 | 0.030 |
Why?
| | Golgi Apparatus | 1 | 2016 | 100 | 0.030 |
Why?
| | Hospitalization | 1 | 2025 | 2199 | 0.030 |
Why?
| | Amyloid | 1 | 2016 | 87 | 0.030 |
Why?
| | tau Proteins | 1 | 2016 | 90 | 0.030 |
Why?
| | Point Mutation | 1 | 1996 | 235 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1995 | 345 | 0.030 |
Why?
| | Immunoblotting | 1 | 1995 | 308 | 0.030 |
Why?
| | Cloning, Molecular | 1 | 1996 | 534 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 1996 | 570 | 0.030 |
Why?
| | Methionine | 1 | 1995 | 160 | 0.030 |
Why?
| | Autoimmunity | 1 | 2020 | 908 | 0.030 |
Why?
| | Hospitals, Teaching | 2 | 1991 | 118 | 0.030 |
Why?
| | Peptides | 1 | 1999 | 985 | 0.030 |
Why?
| | Dentate Gyrus | 1 | 2013 | 37 | 0.030 |
Why?
| | Coloring Agents | 1 | 2013 | 87 | 0.030 |
Why?
| | Azepines | 1 | 2013 | 90 | 0.030 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2013 | 80 | 0.030 |
Why?
| | Alanine | 1 | 2013 | 152 | 0.020 |
Why?
| | Poliomyelitis | 1 | 1993 | 37 | 0.020 |
Why?
| | Functional Laterality | 1 | 2013 | 223 | 0.020 |
Why?
| | District of Columbia | 1 | 2012 | 28 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2167 | 0.020 |
Why?
| | Recurrence | 1 | 2016 | 1060 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2844 | 0.020 |
Why?
| | Behavior, Animal | 1 | 2016 | 501 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1353 | 0.020 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2012 | 16 | 0.020 |
Why?
| | Ambulances | 1 | 2012 | 51 | 0.020 |
Why?
| | Rhinovirus | 1 | 2012 | 58 | 0.020 |
Why?
| | Escherichia coli | 1 | 1996 | 815 | 0.020 |
Why?
| | Octoxynol | 1 | 1991 | 13 | 0.020 |
Why?
| | Centrifugation, Density Gradient | 1 | 1991 | 41 | 0.020 |
Why?
| | Methylation | 1 | 2012 | 230 | 0.020 |
Why?
| | Deoxycholic Acid | 1 | 1991 | 14 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 852 | 0.020 |
Why?
| | Detergents | 1 | 1991 | 44 | 0.020 |
Why?
| | Virulence | 1 | 2012 | 267 | 0.020 |
Why?
| | DEAD Box Protein 58 | 1 | 2010 | 9 | 0.020 |
Why?
| | Solubility | 1 | 1991 | 245 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2025 | 10811 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2013 | 840 | 0.020 |
Why?
| | DEAD-box RNA Helicases | 1 | 2010 | 76 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2010 | 372 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 2010 | 216 | 0.020 |
Why?
| | Chick Embryo | 1 | 1988 | 130 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2010 | 385 | 0.020 |
Why?
| | Brain Concussion | 1 | 2016 | 574 | 0.020 |
Why?
| | Hippocampus | 1 | 2013 | 895 | 0.020 |
Why?
| | Hospital Mortality | 1 | 1991 | 911 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2010 | 596 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 1991 | 641 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 4295 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2012 | 3015 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2010 | 828 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2010 | 1164 | 0.010 |
Why?
| | Fibroblasts | 1 | 1988 | 996 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2010 | 3412 | 0.010 |
Why?
| | Macromolecular Substances | 1 | 2002 | 229 | 0.010 |
Why?
| | Surface Properties | 1 | 2002 | 413 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 1991 | 2069 | 0.010 |
Why?
| | Brefeldin A | 1 | 1997 | 10 | 0.010 |
Why?
| | Oximes | 1 | 1997 | 24 | 0.010 |
Why?
| | Cyclopentanes | 1 | 1997 | 19 | 0.010 |
Why?
| | Genetic Techniques | 1 | 1997 | 64 | 0.010 |
Why?
| | Benzimidazoles | 1 | 1997 | 170 | 0.010 |
Why?
| | Sulfonamides | 1 | 1997 | 513 | 0.010 |
Why?
| | Helper Viruses | 1 | 1992 | 2 | 0.010 |
Why?
| | Reading Frames | 1 | 1992 | 3 | 0.010 |
Why?
| | Virion | 1 | 1992 | 93 | 0.010 |
Why?
| | England | 1 | 1991 | 97 | 0.010 |
Why?
| | Peer Review | 1 | 1991 | 49 | 0.010 |
Why?
| | Trauma Severity Indices | 1 | 1991 | 106 | 0.010 |
Why?
| | Transfection | 1 | 1992 | 945 | 0.010 |
Why?
| | United Kingdom | 1 | 1991 | 318 | 0.010 |
Why?
| | Aged, 80 and over | 2 | 1991 | 7635 | 0.000 |
Why?
| | Central Nervous System | 1 | 1991 | 258 | 0.000 |
Why?
| | Infant | 2 | 1991 | 9465 | 0.000 |
Why?
| | Child, Preschool | 2 | 1991 | 11074 | 0.000 |
Why?
| | Survival Rate | 1 | 1991 | 1972 | 0.000 |
Why?
| | Child | 2 | 1991 | 21935 | 0.000 |
Why?
|
|
Barton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|